I don’t think the US market is as easy to crack as
some people hope. Aussie biotechs such as AVH,
PNV, NXS have found the going tough, despite
great best in market products and their share
price has reacted accordingly.
We can’t blame Covid for ever.
Further CelGro® nerve clinical trial data from all patients at 12 months, page-63
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
-0.020(2.92%) |
Mkt cap ! $159.0M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 65.0¢ | $245.7K | 371.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15000 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 12621 | 2 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |